MOLECULIN BIOTECH INC (MBRX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.71+5.09%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · MBRX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -15.6% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has erratic recent earnings surprises and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
MBRX — earnings miss
Dated 2026-08-14
Results of Operations and Financial Condition. On August 14, 2026, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026 and recent operational highlights. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.
Why it matters: Reaching the 90-patient milestone is key for the trial's next steps. It confirms ongoing interest and engagement in the study.
Supportive ifEnrollment reaches 90 patients in Part A of the MIRACLE trial by September 2026.
Worry ifEnrollment fails to reach 90 patients by the end of September 2026.
Why it matters: Updates on cash will show if the company can sustain operations and fund trials. This affects investor confidence.
Supportive ifManagement says they have enough cash to run operations into the first quarter of 2027.
Worry ifManagement indicates cash will run out before the first quarter of 2027.
Why it matters: Starting Part B is crucial for advancing Annamycin's development. It signals confidence in the trial's success.
Supportive ifPart B of the MIRACLE trial starts in the first half of 2027 as planned.
Worry ifPart B initiation is delayed beyond the first half of 2027.
Why it matters: Updates on cash flow will indicate financial health and ability to fund trials.
Watch forCash flow is better due to successful fundraising from the recent offering.
Also watch forCash flow worsens or fails to stabilize after the capital raise.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$288 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $924 loss on $10,000 · 9.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,709 loss on $10,000 · 97.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Cash flow trends show if the company can control costs. This is important for drug development.
Worry ifCash flow from operations remains negative, worse than -$7.2M.
Less concerning ifCash flow from operations improves to less than -$5M. This shows better cost management.
Why it matters: The unblinded data will show how well Annamycin works compared to control. It can influence future development and partnerships.
Watch forUnblinded data shows higher remission rates. This is compared to the control group from December 2026 to February 2027.
Also watch forUnblinded data shows no big difference in remission rates. This is when compared to the control group.
Why it matters: Updates on clinical trials will show how drug development is going. This is key for future money.
Supportive ifManagement shares good news from a cancer drug trial.
Worry ifManagement reports problems or delays in cancer drug trials.
Why it matters: Updates on capital raising will show if Moleculin can fund its operations. This is crucial for its survival.
Supportive ifManagement tells us when they use warrants or issue new shares.
Worry ifNo news on raising capital or more delays in funding.
Why it matters: Earnings results will show if the company continues to miss revenue targets. This is key for investor confidence.
Worry ifThe earnings report shows revenue below $0.0. This means there are no sales.
Less concerning ifThe earnings report shows revenue above $0.0. This means sales may be improving.
Why it matters: Strong interest from doctors could boost Annamycin's market use and sales.
Supportive ifSurveys show doctors are likely to prescribe Annamycin at 6 out of 7.
Worry ifDoctor interest is falling. Fewer doctors are likely to prescribe it.
Why it matters: Managing cash flow is key to keeping operations going as trial costs rise.
Worry ifCash and cash equivalents remain above $10M after Q2 2026.
Less concerning ifCash and cash equivalents drop below $10M after Q2 2026.